文献速递胸部肿瘤乳腺癌消化系统肿瘤

2001-2019年美国HIV感染者的癌症治疗差异

Cancer Treatment Disparities in People With HIV in the United States, 2001-2019.
PubMed 文献 · J Clin Oncol · 2024-03-21

基于HIV/AIDS癌症匹配研究,比较2001-2019年HIV感染者与非感染者接受癌症治疗及局部期标准治疗的差异。HIV感染者多种癌症未接受治疗的可能性更高,乳腺癌、结肠癌和前列腺癌的差异随时间缩小,但弥漫大B细胞淋巴瘤、宫颈癌和肺癌在2014-2019年仍持续存在差异。

要点

  • HIV感染者宫颈癌、弥漫大B细胞淋巴瘤、霍奇金淋巴瘤、肺癌、前列腺癌、结肠癌和乳腺癌未接受癌症治疗的几率均高于非感染者。
  • 局部期癌症中关联相似,但肛门癌未见差异。
  • 乳腺癌、结肠癌和前列腺癌的治疗差异随时间显著下降,但2014-2019年弥漫大B细胞淋巴瘤、宫颈癌和肺癌仍存在差异。

核心结论

  • 在美国,HIV感染者接受癌症治疗方面的差异在当代仍然持续存在。
  • 亟需解决HIV感染者接受癌症治疗不公平的问题。

研究设计与样本

  • 研究使用HIV/AIDS癌症匹配研究的数据,该研究为基于人群的HIV与癌症登记链接。
  • 分析纳入2001至2019年诊断为弥漫大B细胞淋巴瘤、霍奇金淋巴瘤以及宫颈癌、肺癌、肛门癌、前列腺癌、结肠癌和女性乳腺癌的患者。
  • HIV感染者共16,334例,非HIV感染者共2,880,955例。
  • 结局包括接受任何癌症治疗以及局部期癌症患者接受标准治疗。

主要发现

  • 与无HIV的癌症患者相比,HIV感染者未接受癌症治疗的调整患病比值比为:宫颈癌aOR 2.03(95%CI 1.52至2.70),弥漫大B细胞淋巴瘤aOR 1.53(95%CI 1.38至1.70),霍奇金淋巴瘤aOR 1.39(95%CI 1.19至1.63),肺癌aOR 1.79(95%CI 1.65至1.93),前列腺癌aOR 1.32(95%CI 1.21至1.44),结肠癌aOR 1.73(95%CI 1.43至2.08),乳腺癌aOR 1.38(95%CI 1.07至1.77)。
  • 在局部期癌症的HIV感染者中观察到相似关联,但肛门癌未见差异。
  • HIV与非HIV感染者未接受癌症治疗的关联随时间显著下降见于乳腺癌、结肠癌和前列腺癌(所有P趋势<.0001)。
  • 2014至2019年,HIV感染者接受弥漫大B细胞淋巴瘤、宫颈癌和肺癌治疗的可能性仍较低。
  • 在HIV感染者中,黑人、注射吸毒者和65岁及以上者接受癌症治疗的可能性更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: People with HIV (PWH) have worse cancer outcomes, partially because of inequities in cancer treatment. We evaluated cancer treatment disparities among PWH, including an assessment of changes in disparities over time. METHODS: We used data from the HIV/AIDS Cancer Match Study, a population-based HIV and cancer registry linkage to examine diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and cancers of the cervix, lung, anus, prostate, colon, and female breast. Outcomes included receipt of (1) any cancer treatment and (2) standard therapy among patients with local-stage cancer. We assessed associations between HIV and each outcome by estimating adjusted prevalence odds ratios (aORs) with 95% CI and trends over time. We identified predictors of nonreceipt of cancer treatment in PWH. RESULTS: From 2001 to 2019, compared with people with cancer without HIV (n = 2,880,955), PWH (n = 16,334) were more likely to not receive cancer treatment for cervical cancer (aOR, 2.03 [95% CI, 1.52 to 2.70]), DLBCL (aOR, 1.53 [95% CI, 1.38 to 1.70]), HL (aOR, 1.39 [95% CI, 1.19 to 1.63]), lung cancer (aOR, 1.79 [95% CI, 1.65 to 1.93]), prostate cancer (aOR, 1.32 [95% CI, 1.21 to 1.44]), colon cancer (aOR, 1.73 [95% CI, 1.43 to 2.08]), and breast cancer (aOR, 1.38 [95% CI, 1.07 to 1.77]). Similar associations were observed in PWH with local-stage cancers although no difference was observed for anal cancers. The association between HIV and nonreceipt of cancer treatment significantly decreased over time for breast, colon, and prostate cancers (all P trend <.0001), but PWH remained less likely to receive treatment in 2014-2019 for DLBCL, cervix, and lung cancers. Among PWH, Black individuals, people who inject drugs, and those 65 years and older were less likely to receive cancer treatment. CONCLUSION: Disparities in receipt of cancer treatment persist for PWH in the United States in contemporary time periods. Solutions to address inequitable receipt of cancer treatment among PWH are urgently needed.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McGee-Avila JK, Suneja G, Engels EA, et al. Cancer Treatment Disparities in People With HIV in the United States, 2001-2019. J Clin Oncol. 2024. PMID: 38513161. doi:10.1200/JCO.23.02366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。